,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04']
destiny-breast04 phase iii trial showed trastuzumab deruxtecan improved both pfs and os in her2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (hr) status versus physician s choice of chemotherapy. #asco22
Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition